Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Ceapro Inc V.CZO

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.


TSXV:CZO - Post by User

Post by Ciaoon Jan 31, 2024 8:49am
149 Views
Post# 35854509

5 major failures that could have been transformative

5 major failures that could have been transformative Lots of excuses, no positive results, this is what a $500K/year CEO delivers

1) functional drink, that was a corporate target for 2020
2) Y-BG, in 2020 a phase 1/2 clinical protocol was planned to be submitted in Q4 2020
https://www.ceapro.com/news/press-releases/detail/199/ceapro-inc-provides-update-on-development-of-an-inhalable)[/url
this appears to be in limbo now
3) NCC, that was a corporate target fof 2020
4) BG pill, if the Italian study was read before the MHI study began, protocol calling for satchets could have been used
5) CoQ10 license, that was a corporate target for H2 2023 (with the CRO gone, so are the so called "serious" discussions?)

OATS, you have the ability to change these results, vote NO to the sham merger, then VOTE out Gilles at the AGM, and we can push for a new CEO
<< Previous
Bullboard Posts
Next >>